News & Updates

Show Multimedia Only
Early gestational diabetes treatment modest at best in preventing adverse neonatal outcomes
Early gestational diabetes treatment modest at best in preventing adverse neonatal outcomes
09 Aug 2023

Treatment of gestational diabetes before 20 weeks’ gestation appears to lead to a modestly lower incidence of a composite of adverse neonatal outcomes as compared with no-immediate treatment, with no substantial differences noted for pregnancy-related hypertension or neonatal lean body mass, as reported in a study.

Early gestational diabetes treatment modest at best in preventing adverse neonatal outcomes
09 Aug 2023
Frequent nut intake delays cognitive decline in older adults
Frequent nut intake delays cognitive decline in older adults
08 Aug 2023
Probiotic supplementation in pregnant women with obesity of little benefit to mothers, babies
Probiotic supplementation in pregnant women with obesity of little benefit to mothers, babies
05 Aug 2023

In pregnant women with obesity, supplementation with multi-strain probiotics does not appear to have favourable effects on the metabolic or inflammatory biomarkers in mothers and on the body composition of their offspring, according to a study.

Probiotic supplementation in pregnant women with obesity of little benefit to mothers, babies
05 Aug 2023
Synbiotics help reduce weight in adults with overweight, obesity
Synbiotics help reduce weight in adults with overweight, obesity
03 Aug 2023
Endometriosis not a risk factor for type 2 diabetes
Endometriosis not a risk factor for type 2 diabetes
02 Aug 2023

The presence of endometriosis does not appear to contribute to an increased risk of type 2 diabetes in women, according to a study.

Endometriosis not a risk factor for type 2 diabetes
02 Aug 2023
Diabetes mellitus is a growing health problem traditionally characterized by peripheral insulin resistance (IR), increased he
Diabetes mellitus is a growing health problem traditionally characterized by peripheral insulin resistance (IR), increased hepatic gluconeogenesis, and impaired pancreatic beta-cell function. However, the pathophysiology of T2DM is complex, and disease progression is linked to factors beyond insulin dysregulation and reduced first-phase insulin response.
02 Aug 2023 byJoanne G. Blanco, MD

Diabetes mellitus is a growing health problem traditionally characterized by peripheral insulin resistance (IR), increased hepatic gluconeogenesis, and impaired pancreatic beta-cell function.1 However, the pathophysiology of T2DM is complex, and disease progression is linked to factors beyond insulin dysregulation and reduced first-phase insulin response.2 Unfortunately, many existing anti-hyperglycemic medications cause side effects such as hypoglycemia and weight gain, which may reduce adherence to treatment. In contrast, ideal diabetes medications would control glycemia without a risk of hypoglycemia, while providing additional beneficial effects on beta-cell function, body weight, lipid profiles, hypertension and cardiovascular risk.3

Diabetes mellitus is a growing health problem traditionally characterized by peripheral insulin resistance (IR), increased hepatic gluconeogenesis, and impaired pancreatic beta-cell function. However, the pathophysiology of T2DM is complex, and disease progression is linked to factors beyond insulin dysregulation and reduced first-phase insulin response.
02 Aug 2023